Disease on EC 1.7.3.3 - factor-independent urate hydroxylase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acatalasia
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Acidosis
Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden.
Acute Kidney Injury
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Acute Kidney Injury
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Acute Kidney Injury
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Acute Kidney Injury
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Acute Kidney Injury
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Acute Kidney Injury
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Acute Kidney Injury
Is it the right time to subject children with acute kidney injury to rasburicase trials?
Acute Kidney Injury
Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients.
Acute Kidney Injury
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Acute Kidney Injury
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Acute Kidney Injury
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Acute Kidney Injury
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Acute Kidney Injury
Rasburicase improves hyperuricemia in infants with acute kidney injury.
Acute Kidney Injury
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Acute Kidney Injury
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Acute Kidney Injury
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Acute Kidney Injury
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Acute Kidney Injury
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Acute Kidney Injury
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Acute Kidney Injury
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Acute Kidney Injury
Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury.
Anaphylaxis
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Anaphylaxis
Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
Anaphylaxis
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
Anaphylaxis
Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project.
Anemia
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Anemia, Hemolytic
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Anemia, Hemolytic
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
Anemia, Hemolytic
Hemolytic anemia following rasburicase administration: a review of published reports.
Anemia, Hemolytic
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Anemia, Hemolytic
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Anemia, Hemolytic
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Anemia, Hemolytic
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Anemia, Hemolytic
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Ankylosis
Divergent patterns of joint remodelling following effective urate-lowering therapy in tophaceous gout.
Arthritis
Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Arthritis
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Arthritis
Investigation on uric acid biosensor model for enzyme layer thickness for the application of arthritis disease diagnosis.
Arthritis
Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory.
Atherosclerosis
Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway.
Bronchial Spasm
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Bronchial Spasm
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Bronchial Spasm
[Bronchospasm as an allergic manifestation after intravenous injection of urate oxidase in a female patient treated for myeloma]
Burkitt Lymphoma
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Burkitt Lymphoma
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Burkitt Lymphoma
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Burkitt Lymphoma
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Carcinogenesis
Catalase and uricase studies on rats during 2-acetylaminofluorene carcinogenesis.
Carcinoma
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
Carcinoma
A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma.
Carcinoma, Hepatocellular
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Carcinoma, Hepatocellular
SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1.
Carcinoma, Hepatocellular
[Distribution, after differential centrifugation, of acid hydrolases, catalase, D-amino acid oxidase and urate oxidase in various Morris hepatomas]
Carcinoma, Ovarian Epithelial
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
catalase deficiency
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
catalase deficiency
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Dehydration
Identification of quasi-stable water molecules near the Thr73-Lys13 catalytic diad of Bacillus sp. TB-90 urate oxidase by X-ray crystallography with controlled humidity.
Dermatitis, Contact
The endogenous danger signal uric Acid augments contact hypersensitivity responses in mice.
Diabetes Insipidus
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Diabetes Mellitus, Type 2
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.
Down Syndrome
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Drug-Related Side Effects and Adverse Reactions
Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project.
Endotoxemia
Impact of uric acid on liver injury and intestinal permeability following resuscitated hemorrhagic shock in rats.
Essential Hypertension
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
factor-independent urate hydroxylase deficiency
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
factor-independent urate hydroxylase deficiency
Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency.
factor-independent urate hydroxylase deficiency
Mouse paracentric inversion In(3)55Rk mutates the urate oxidase gene.
factor-independent urate hydroxylase deficiency
Two independent mutational events in the loss of urate oxidase during hominoid evolution.
factor-independent urate hydroxylase deficiency
Uricase deficiency causes mild and multiple organ injuries in rats.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Hemolysis and methemoglobinemia secondary to rasburicase administration.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Rasburicase: a potent uricolytic agent.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]
Glucosephosphate Dehydrogenase Deficiency
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Glucosephosphate Dehydrogenase Deficiency
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Glucosephosphate Dehydrogenase Deficiency
Hemolysis and methemoglobinemia secondary to rasburicase administration.
Glucosephosphate Dehydrogenase Deficiency
Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient.
Glucosephosphate Dehydrogenase Deficiency
Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.
Glucosephosphate Dehydrogenase Deficiency
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
Glucosephosphate Dehydrogenase Deficiency
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Glucosephosphate Dehydrogenase Deficiency
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Glucosephosphate Dehydrogenase Deficiency
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Glucosephosphate Dehydrogenase Deficiency
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
Glucosephosphate Dehydrogenase Deficiency
[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]
Glycogen Storage Disease Type II
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Gout
A Case Report of Immunosuppressant Medication?Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol?Conjugated Uricase Enzyme Pegloticase.
Gout
A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
Gout
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Gout
A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma.
Gout
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Gout
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Gout
Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.
Gout
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Gout
Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
Gout
Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices.
Gout
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Gout
Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis.
Gout
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
Gout
Economic analysis of uricase production under uncertainty: Contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle).
Gout
Effect of surfactants and inducers on increased uricase production under submerged fermentations (SMF) by Bacillus cereus.
Gout
Enhancement of Pharmaceutical Urate Oxidase Thermostability by Rational Design of De Novo Disulfide Bridge.
Gout
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Gout
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Gout
ISOLATION, SCREENING AND PRODUCTION STUDIES OF URICASE PRODUCING BACTERIA FROM POULTRY SOURCES.
Gout
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4.
Gout
Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy.
Gout
Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
Gout
New insight into the molecular mechanism of the trehalose effect on urate oxidase stability.
Gout
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice.
Gout
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Gout
Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.
Gout
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Gout
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Gout
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Gout
Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Gout
Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys.
Gout
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Gout
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Gout
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Gout
Site-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coli.
Gout
Spatial Confined Synergistic Enzymes with Enhanced Uricolytic Performance and Reduced Toxicity for Effective Gout Treatment.
Gout
Structural and biochemical insights into a hyperthermostable urate oxidase from Thermobispora bispora for hyperuricemia and gout therapy.
Gout
Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol.
Gout
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Gout
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Gout
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
Gout
Treatment of gout patients with impairment of renal function: a systematic literature review.
Gout
Urate crystal degradation for treatment of gout: a nanoparticulate combination therapy approach.
Gout
Uricase and other novel agents for the management of patients with treatment-failure gout.
Gout
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Gout
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Gout
Uricases as therapeutic agents to treat refractory gout: Current states and future directions.
Gout
[Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase]
Graft vs Host Disease
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Heart Failure
Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery.
Hematologic Neoplasms
A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma.
Hematologic Neoplasms
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Hematologic Neoplasms
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Hematologic Neoplasms
Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies.
Hematologic Neoplasms
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Hematologic Neoplasms
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hematologic Neoplasms
Current management of gout in patients unresponsive or allergic to allopurinol.
Hematologic Neoplasms
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Hematologic Neoplasms
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Hematologic Neoplasms
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Hematologic Neoplasms
Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.
Hematologic Neoplasms
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Hematologic Neoplasms
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Hematologic Neoplasms
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Hematologic Neoplasms
Prevention and treatment of hyperuricemia in hematological malignancies.
Hematologic Neoplasms
Rasburicase for the treatment of tumor lysis in hematological malignancies.
Hematologic Neoplasms
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Hematologic Neoplasms
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Hematologic Neoplasms
Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
Hematologic Neoplasms
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Hematologic Neoplasms
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
Hematologic Neoplasms
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Hematologic Neoplasms
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Hematologic Neoplasms
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Hematologic Neoplasms
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Hematologic Neoplasms
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
Hematologic Neoplasms
[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]
Hematologic Neoplasms
[Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
Hemolytic-Uremic Syndrome
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.
Hemophilia A
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Hepatitis C
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Hepatitis C
Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient.
Hepatomegaly
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Hepatomegaly
Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding.
Hepatomegaly
The hypolipidemic peroxisome-proliferating drug, bis(carboxymethylthio)-1.10 decane, a dicarboxylic metabolite of tiadenol, is activated to an acylcoenzyme A thioester.
Hyperphosphatemia
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Hypersensitivity
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
Hypersensitivity
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Hypersensitivity
Purification, quantification and gene expression of urate oxidases in rust-infected bean leaves.
Hypersensitivity
Rasburicase : a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Hypersensitivity
Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
Hypersensitivity
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Hypersensitivity
Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach.
Hypersensitivity
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Hypersensitivity
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Hypersensitivity
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Hypertension
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Hypertension
Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Hypertension
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Hypertension
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Hypertension
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.
Hypertension
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Hypertension
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Hypertension
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Infections
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Infections
Effect of rust infection on levels of uricase, allantoinase and ureides in susceptible and hypersensitive bean leaves.
Infections
Expression pattern of uricase II gene during root nodule development in Phaseolus vulgaris.
Infections
Immunogold localization of nodule-specific uricase in developing soybean root nodules.
Infections
Purification, quantification and gene expression of urate oxidases in rust-infected bean leaves.
Insulin Resistance
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Kidney Calculi
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Kidney Failure, Chronic
Expansion of Urease- and Uricase-Containing, Indole- and p-Cresol-Forming and Contraction of Short-Chain Fatty Acid-Producing Intestinal Microbiota in ESRD.
Kidney Failure, Chronic
Interference in colorimetric reactions for measuring hydrogen peroxide.
Lesch-Nyhan Syndrome
Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome.
Lesch-Nyhan Syndrome
[Treatment of high urinary xanthine excretion with increased amounts of allopurinol and with urate oxidase in a child with Lesch-Nyhan syndrome (author's transl)]
Leukemia
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
Leukemia
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Leukemia
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Leukemia
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Leukemia
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Leukemia
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Leukemia
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Leukemia
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Leukemia
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Leukemia
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Leukemia
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Leukemia
[Anaphylaxis-like manifestations after intravenous injection of urate oxidase in an asthmatic child with acute leukemia]
Leukemia, Lymphocytic, Chronic, B-Cell
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Leukemia, Lymphocytic, Chronic, B-Cell
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Leukemia, Myeloid, Acute
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Leukemia, Myeloid, Acute
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Leukocytosis
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Leukocytosis
Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations.
Lymphoma
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Lymphoma
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Lymphoma
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Lymphoma
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Lymphoma
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Lymphoma
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Lymphoma
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Lymphoma
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Lymphoma
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Lymphoma, Non-Hodgkin
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient.
Lymphoma, Non-Hodgkin
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Lymphoma, Non-Hodgkin
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Lymphoma, Non-Hodgkin
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Lymphoma, Non-Hodgkin
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Lymphoma, Non-Hodgkin
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Lymphoma, Non-Hodgkin
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Malaria, Vivax
Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision.
Menkes Kinky Hair Syndrome
Urate oxidase activity and copper content in the liver of macular mutant mouse, a model animal for human congenital copper deficiency, Menkes' kinky hair disease.
Mesothelioma
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Metabolic Syndrome
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Metabolic Syndrome
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Methemoglobinemia
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Methemoglobinemia
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Methemoglobinemia
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Methemoglobinemia
Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient.
Methemoglobinemia
Inherited catalase deficiency: Is it benign or a factor in various age related disorders?
Methemoglobinemia
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
Methemoglobinemia
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Methemoglobinemia
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Methemoglobinemia
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Methemoglobinemia
Methemoglobinemia secondary to rasburicase in cancer: Non drug-related oxidative stress.
Methemoglobinemia
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Methemoglobinemia
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Methemoglobinemia
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Methemoglobinemia
Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.
Methemoglobinemia
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Methemoglobinemia
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Methemoglobinemia
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Methemoglobinemia
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Mucositis
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Myeloproliferative Disorders
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
Myeloproliferative Disorders
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Neoplasm Metastasis
Brief report: The uricase mutation in humans increases our risk for cancer growth.
Neoplasms
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
Neoplasms
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
Neoplasms
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Neoplasms
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
Neoplasms
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Neoplasms
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Neoplasms
A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Neoplasms
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Neoplasms
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Neoplasms
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
Neoplasms
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
Neoplasms
A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults.
Neoplasms
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Neoplasms
Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
Neoplasms
Acute renal failure from xanthine nephropathy during management of acute leukemia.
Neoplasms
Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
Neoplasms
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Neoplasms
Allantoin reduces cell death induced by cisplatin: possible implications for tumor lysis syndrome management.
Neoplasms
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Neoplasms
Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Neoplasms
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Neoplasms
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Neoplasms
Brief report: The uricase mutation in humans increases our risk for cancer growth.
Neoplasms
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Neoplasms
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Neoplasms
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Neoplasms
Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Neoplasms
Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer.
Neoplasms
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Neoplasms
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Neoplasms
Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Neoplasms
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.
Neoplasms
Designing and Engineering of a Site-specific Incorporation of a Keto Group in Uricase.
Neoplasms
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Neoplasms
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Neoplasms
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Neoplasms
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Neoplasms
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
Neoplasms
Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome.
Neoplasms
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Neoplasms
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Neoplasms
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Neoplasms
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Neoplasms
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Neoplasms
Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Neoplasms
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Neoplasms
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Neoplasms
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Neoplasms
Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli.
Neoplasms
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Neoplasms
Enhancement of Pharmaceutical Urate Oxidase Thermostability by Rational Design of De Novo Disulfide Bridge.
Neoplasms
Erythrocyte hemighosts in a patient with tumor lysis syndrome: One train may hide another.
Neoplasms
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Neoplasms
Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Neoplasms
Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
Neoplasms
Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Neoplasms
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Neoplasms
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Neoplasms
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Neoplasms
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Neoplasms
Heterologous expression of recombinant urate oxidase using the intein-mediated protein purification in Pichia pastoris.
Neoplasms
Hyperxanthinemia interferes with serum uric acid determinations by the uricase method.
Neoplasms
I.V. ascorbic acid for treatment of apparent rasburicase-induced methemoglobinemia in a patient with acute kidney injury and assumed glucose-6-phosphate dehydrogenase deficiency.
Neoplasms
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Neoplasms
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Neoplasms
Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Neoplasms
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Neoplasms
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Neoplasms
Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Neoplasms
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4.
Neoplasms
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Neoplasms
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Neoplasms
Methemoglobinemia secondary to rasburicase in cancer: Non drug-related oxidative stress.
Neoplasms
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
Neoplasms
Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252.
Neoplasms
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Neoplasms
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Neoplasms
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Neoplasms
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Neoplasms
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Neoplasms
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Neoplasms
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Neoplasms
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Neoplasms
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Neoplasms
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Neoplasms
Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Neoplasms
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy.
Neoplasms
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Neoplasms
Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis.
Neoplasms
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Neoplasms
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Neoplasms
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Neoplasms
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Neoplasms
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Neoplasms
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Neoplasms
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Neoplasms
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Neoplasms
Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
Neoplasms
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Neoplasms
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Neoplasms
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Neoplasms
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Neoplasms
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.
Neoplasms
Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Neoplasms
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Neoplasms
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Neoplasms
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
Neoplasms
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Neoplasms
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Neoplasms
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Neoplasms
Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Neoplasms
Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision.
Neoplasms
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.
Neoplasms
Review of the Literature Examining the Association of Serum Uric Acid with Osteoporosis and Mechanistic Insights into Its Effect on Bone Metabolism.
Neoplasms
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Neoplasms
Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
Neoplasms
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Neoplasms
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Neoplasms
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Neoplasms
Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Neoplasms
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Neoplasms
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Neoplasms
Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.
Neoplasms
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Neoplasms
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Neoplasms
Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist.
Neoplasms
Strengthening the stability of a tunnel-shaped homotetramer protein with nanogels.
Neoplasms
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
Neoplasms
The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase.
Neoplasms
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
Neoplasms
The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.
Neoplasms
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Neoplasms
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Neoplasms
Things We Do for No Reason: Rasburicase for Adult Patients With Tumor Lysis Syndrome.
Neoplasms
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Neoplasms
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica.
Neoplasms
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Neoplasms
Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Neoplasms
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Neoplasms
Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.
Neoplasms
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Neoplasms
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Neoplasms
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Neoplasms
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Neoplasms
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Neoplasms
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Neoplasms
Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.
Neoplasms
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Neoplasms
Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
Neoplasms
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Neoplasms
Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
Neoplasms
[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]
Neoplasms
[Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
Neoplasms
[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome]
Neoplasms
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
Neoplasms
[The current status of the treatment of tumor lysis syndrome--the role of rasburicase (Fasturtec)]
Neuroinflammatory Diseases
Targeting Uric Acid Prevents Brain Injury and Anxiety in a Rat Model of Hemorrhagic Shock.
Obesity
Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes.
Obesity
Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology.
Obesity
Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.
Overweight
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Overweight
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Pancreatitis
Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions.
Pancreatitis
Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.
Pancytopenia
Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Pneumonia
Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.
Pneumonia, Bacterial
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Polyuria
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
European experience in the treatment of hyperuricemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of impending tumor lysis with single-dose rasburicase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Prostatic Neoplasms
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
Proteinuria
Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.
Pruritus
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Renal Insufficiency
Acute spontaneous tumor lysis syndrome in a patient with Crohn's disease taking immunosuppressants.
Renal Insufficiency
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Renal Insufficiency
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Renal Insufficiency
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Renal Insufficiency
Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes.
Renal Insufficiency
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Renal Insufficiency
Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy?
Renal Insufficiency
Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
Renal Insufficiency
Metastatic gestational trophoblastic neoplasia complicated by tumor lysis syndrome, heart failure, and thyrotoxicosis: a case report.
Renal Insufficiency
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Renal Insufficiency
Protective effect of urate oxidase on uric acid induced-monocyte apoptosis.
Renal Insufficiency
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Renal Insufficiency
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Renal Insufficiency
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Renal Insufficiency
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Renal Insufficiency
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Renal Insufficiency
Treatment of gout patients with impairment of renal function: a systematic literature review.
Renal Insufficiency
Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Renal Insufficiency
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Renal Insufficiency
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Renal Insufficiency
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Renal Insufficiency
[Acute hyperleukocytic lymphoblastic leukemia (greater than or equal to 100,000 leukocytes/mm3). Metabolic changes during induction treatment. Study, prevention and treatment]
Renal Insufficiency
[Influence of renal insufficiency on the pharmokinetics and metabolism of urate oxidase]
Renal Insufficiency, Chronic
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Renal Insufficiency, Chronic
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Renal Insufficiency, Chronic
Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Respiratory Insufficiency
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Rhabdomyolysis
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Seizures
Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole- and pilocarpine-induced seizures in mice.
Seizures
Uric acid is released in the brain during seizure activity and increases severity of seizures in a mouse model for acute limbic seizures.
Starvation
An electron microscopic and enzymic study of rat liver peroxisomal nucleoid core and its association with urate oxidase.
Starvation
Earliest evidence of caries lesion in hominids reveal sugar-rich diet for a Middle Miocene dryopithecine from Europe.
Starvation
Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids.
Stroke
Rasburicase improves hyperuricemia in patients with acute kidney injury secondary to rhabdomyolysis caused by ecstasy intoxication and exertional heat stroke.
Testicular Neoplasms
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Thrombocytopenia
Complications of "Very High" Leukocytosis in Pediatric Acute Leukemia Patients Managed Without Rasburicase and Leukopheresis.
Tumor Lysis Syndrome
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay.
Tumor Lysis Syndrome
A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
Tumor Lysis Syndrome
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Tumor Lysis Syndrome
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
Tumor Lysis Syndrome
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Tumor Lysis Syndrome
A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Tumor Lysis Syndrome
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Tumor Lysis Syndrome
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Tumor Lysis Syndrome
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
Tumor Lysis Syndrome
A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults.
Tumor Lysis Syndrome
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Tumor Lysis Syndrome
Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
Tumor Lysis Syndrome
Acute renal failure from xanthine nephropathy during management of acute leukemia.
Tumor Lysis Syndrome
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
Tumor Lysis Syndrome
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
Tumor Lysis Syndrome
Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Tumor Lysis Syndrome
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Tumor Lysis Syndrome
B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
Tumor Lysis Syndrome
Catalase deficiency may complicate urate oxidase (rasburicase) therapy.
Tumor Lysis Syndrome
Cloning, expression and purification of recombinant uricase enzyme from Pseudomonas aeruginosa Ps43 using Escherichia coli.
Tumor Lysis Syndrome
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Tumor Lysis Syndrome
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Tumor Lysis Syndrome
Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Tumor Lysis Syndrome
Computational Approach for Rational Design of Fusion Uricase with PAS Sequences.
Tumor Lysis Syndrome
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Tumor Lysis Syndrome
Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Tumor Lysis Syndrome
Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
Tumor Lysis Syndrome
Decreasing Inappropriate Use of Rasburicase to Promote Cost-Effective Care.
Tumor Lysis Syndrome
Designing and Engineering of a Site-specific Incorporation of a Keto Group in Uricase.
Tumor Lysis Syndrome
Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.
Tumor Lysis Syndrome
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Tumor Lysis Syndrome
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
Tumor Lysis Syndrome
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
Tumor Lysis Syndrome
Effectiveness of a single fixed dose of rasburicase 3mg in the management of tumour lysis syndrome.
Tumor Lysis Syndrome
Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Tumor Lysis Syndrome
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Tumor Lysis Syndrome
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Tumor Lysis Syndrome
EFFICACY OF RASBURICASE THERAPY IN OBSTRUCTIVE NEPHROPATHY FROM RENAL CALCULI: A NOVEL THERAPEUTIC OPTION.
Tumor Lysis Syndrome
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
Tumor Lysis Syndrome
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Tumor Lysis Syndrome
Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli.
Tumor Lysis Syndrome
Emerging therapies in the long-term management of hyperuricaemia and gout.
Tumor Lysis Syndrome
Erythrocyte hemighosts in a patient with tumor lysis syndrome: One train may hide another.
Tumor Lysis Syndrome
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Tumor Lysis Syndrome
Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Tumor Lysis Syndrome
Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
Tumor Lysis Syndrome
Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Tumor Lysis Syndrome
Evolutionary history and metabolic insights of ancient mammalian uricases.
Tumor Lysis Syndrome
Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.
Tumor Lysis Syndrome
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Tumor Lysis Syndrome
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Tumor Lysis Syndrome
Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.
Tumor Lysis Syndrome
Heterologous expression of recombinant urate oxidase using the intein-mediated protein purification in Pichia pastoris.
Tumor Lysis Syndrome
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Tumor Lysis Syndrome
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Tumor Lysis Syndrome
Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Tumor Lysis Syndrome
Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis.
Tumor Lysis Syndrome
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Tumor Lysis Syndrome
Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Tumor Lysis Syndrome
Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.
Tumor Lysis Syndrome
Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review.
Tumor Lysis Syndrome
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
Tumor Lysis Syndrome
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Tumor Lysis Syndrome
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
Tumor Lysis Syndrome
Prevention and treatment of hyperuricemia in hematological malignancies.
Tumor Lysis Syndrome
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Tumor Lysis Syndrome
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Tumor Lysis Syndrome
Rare Case of Transcutaneous Oxygen Desaturation in a Cancer Patient: A Case Report and Diagnostic Approach for a Recurrent Problem.
Tumor Lysis Syndrome
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Tumor Lysis Syndrome
Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency.
Tumor Lysis Syndrome
Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
Tumor Lysis Syndrome
Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Tumor Lysis Syndrome
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Tumor Lysis Syndrome
Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis.
Tumor Lysis Syndrome
Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS.
Tumor Lysis Syndrome
Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis.
Tumor Lysis Syndrome
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Tumor Lysis Syndrome
Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
Tumor Lysis Syndrome
Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.
Tumor Lysis Syndrome
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency.
Tumor Lysis Syndrome
Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.
Tumor Lysis Syndrome
Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.
Tumor Lysis Syndrome
Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.
Tumor Lysis Syndrome
Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.
Tumor Lysis Syndrome
Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Tumor Lysis Syndrome
Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Tumor Lysis Syndrome
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Tumor Lysis Syndrome
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Tumor Lysis Syndrome
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Tumor Lysis Syndrome
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.
Tumor Lysis Syndrome
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Tumor Lysis Syndrome
Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Tumor Lysis Syndrome
Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome.
Tumor Lysis Syndrome
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Tumor Lysis Syndrome
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Tumor Lysis Syndrome
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Tumor Lysis Syndrome
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.
Tumor Lysis Syndrome
Renal Calculi: An Unusual Presentation of T-Cell Acute Lymphoblastic Leukemia.
Tumor Lysis Syndrome
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Tumor Lysis Syndrome
Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
Tumor Lysis Syndrome
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Tumor Lysis Syndrome
Single 4.5?mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Tumor Lysis Syndrome
Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Tumor Lysis Syndrome
Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Tumor Lysis Syndrome
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
Tumor Lysis Syndrome
Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.
Tumor Lysis Syndrome
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Tumor Lysis Syndrome
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Tumor Lysis Syndrome
Strengthening the stability of a tunnel-shaped homotetramer protein with nanogels.
Tumor Lysis Syndrome
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
Tumor Lysis Syndrome
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
Tumor Lysis Syndrome
The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.
Tumor Lysis Syndrome
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Tumor Lysis Syndrome
Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase.
Tumor Lysis Syndrome
Things We Do for No Reason: Rasburicase for Adult Patients With Tumor Lysis Syndrome.
Tumor Lysis Syndrome
Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report.
Tumor Lysis Syndrome
Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica.
Tumor Lysis Syndrome
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Tumor Lysis Syndrome
Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Tumor Lysis Syndrome
Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary.
Tumor Lysis Syndrome
Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report.
Tumor Lysis Syndrome
Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature.
Tumor Lysis Syndrome
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Tumor Lysis Syndrome
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Tumor Lysis Syndrome
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Tumor Lysis Syndrome
Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.
Tumor Lysis Syndrome
Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene.
Tumor Lysis Syndrome
Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
Tumor Lysis Syndrome
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Tumor Lysis Syndrome
Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
Tumor Lysis Syndrome
[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome]
Tumor Lysis Syndrome
[Role of uric acid in hypertension and in the progression of chronic renal disease.]
Tumor Lysis Syndrome
[Single-dose rasburicase as treatment for tumor lysis syndrome in two patients]
Uremia
[Value of addition of a fungal urate oxidase to the dietary treatment of chronic uremia]
Urolithiasis
Dissolution of extensive urolithiasis: extending the utility of rasburicase can avoid the need for surgical intervention and renal replacement therapy.
Urticaria
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Ventilator-Induced Lung Injury
Pre-treatment with allopurinol or uricase attenuates barrier dysfunction but not inflammation during murine ventilator-induced lung injury.
Vitamin A Deficiency
Effects of vitamin A deficiency on selected xenobiotic-metabolizing enzymes and defenses against oxidative stress in mouse liver.
html completed